Age: 81.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Pain, Rash, Vaccination site erythema, Vaccination site pruritus
Clinical narrative: soreness; Some redness; She has a 4 to 5" bullseye-looking redness at the injection site with an itchy head-to-toe rash "almost measles looking" with spots/blotches; She has a 4 to 5" bullseye-looking redness at the injection site with an itchy head-to-toe rash "almost measles looking" with spots/blotches; She has a 4 to 5" bullseye-looking redness at the injection site with an itchy head-to-toe rash "almost measles looking" with spots/blotches; This spontaneous case was reported by a patient and describes the occurrence of PAIN (soreness), ERYTHEMA (Some redness), VACCINATION SITE PRURITUS (She has a 4 to 5" bullseye-looking redness at the injection site with an itchy head-to-toe rash "almost measles looking" with spots/blotches), RASH (She has a 4 to 5" bullseye-looking redness at the injection site with an itchy head-to-toe rash "almost measles looking" with spots/blotches) and VACCINATION SITE ERYTHEMA (She has a 4 to 5" bullseye-looking redness at the injection site with an itchy head-to-toe rash "almost measles looking" with spots/blotches) in an 81-year-old female patient who received mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: RSV Vaccine in 2023; for COVID-19 prophylaxis: Moderna COVID-19 Vaccine in 2023. Past adverse reactions to the above products included Polymyalgia with Moderna COVID-19 Vaccine and RSV Vaccine. Concurrent medical conditions included Polymyalgia. Concomitant products included PREDNISONE for Polymyalgia.    On 28-Sep-2024, the patient received dose of mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (unknown route) .5 milliliter. On an unknown date, the patient experienced PAIN (soreness), ERYTHEMA (Some redness), VACCINATION SITE PRURITUS (She has a 4 to 5" bullseye-looking redness at the injection site with an itchy head-to-toe rash "almost measles looking" with spots/blotches), RASH (She has a 4 to 5" bullseye-looking redness at the injection site with an itchy head-to-toe rash "almost measles looking" with spots/blotches) and VACCINATION SITE ERYTHEMA (She has a 4 to 5" bullseye-looking redness at the injection site with an itchy head-to-toe rash "almost measles looking" with spots/blotches). At the time of the report, PAIN (soreness), ERYTHEMA (Some redness), VACCINATION SITE PRURITUS (She has a 4 to 5" bullseye-looking redness at the injection site with an itchy head-to-toe rash "almost measles looking" with spots/blotches), RASH (She has a 4 to 5" bullseye-looking redness at the injection site with an itchy head-to-toe rash "almost measles looking" with spots/blotches) and VACCINATION SITE ERYTHEMA (She has a 4 to 5" bullseye-looking redness at the injection site with an itchy head-to-toe rash "almost measles looking" with spots/blotches) had not resolved.        For mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (Unknown), the reporter did not provide any causality assessments.   It was reported that patient always received Moderna COVID-19 vaccines. The reporter stated patient received her Moderna vaccine and ended up with a very severe rash that was not getting better. She had a 4 to 5" bullseye-looking redness at the injection site with an itchy head-to-toe rash "almost measles looking" with spots/blotches. The reporter stated that the patient's rash seemed to be getting better but got worse again. The reporter stated that last year, when patient received her Moderna COVID vaccine and the RSV vaccine two weeks later, her polymyalgia flared up afterwards.  The treatment medication was not reported by reporter.   This case was linked to US-MODERNATX, INC.-MOD-2024-774728, US-MODERNATX, INC.-MOD-2024-774734 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-774734:Same reporter US-MODERNATX, INC.-MOD-2024-774728:Same reporter different patient